These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18312403)

  • 1. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
    Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C
    Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO.
    Min JH; Waters P; Vincent A; Lee S; Y Shin H; H Lee K; Kim BJ
    Acta Neurol Scand; 2012 Oct; 126(4):287-91. PubMed ID: 22309305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis.
    Constantinescu CS; Freitag P; Kappos L
    Mult Scler; 2000 Dec; 6(6):378-81. PubMed ID: 11212132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses.
    Mostert JP; Ramsaransing GS; Heersema DJ; Heerings M; Wilczak N; De Keyser J
    J Neurol Sci; 2005 Apr; 231(1-2):41-4. PubMed ID: 15792819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
    O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
    Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
    Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis.
    Liu B; Shen Y; Xiao K; Tang Y; Cen L; Wei J
    Neurol Res; 2012 Mar; 34(2):163-71. PubMed ID: 22333889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).
    Haas J; Firzlaff M
    Eur J Neurol; 2005 Jun; 12(6):425-31. PubMed ID: 15885045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.
    Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu G; Martinelli V; Milani N; Milanese C; Moiola L; Patti F; Pilato V; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
    Mult Scler; 2005 Aug; 11(4):420-4. PubMed ID: 16042224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum uric acid levels in multiple sclerosis patients inversely correlate with disability.
    Guerrero AL; Gutiérrez F; Iglesias F; Martín-Polo J; Merino S; Martín-Serradilla JI; Laherrán E; Tejero MA
    Neurol Sci; 2011 Apr; 32(2):347-50. PubMed ID: 21327401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
    Mehrpour M; Akhoundi FH; Delgosha M; Keyvani H; Motamed MR; Sheibani B; Meysamie A
    Neurologist; 2015 Oct; 20(4):57-60. PubMed ID: 26468869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uric acid: a potential biomarker of multiple sclerosis and of its disability.
    Moccia M; Lanzillo R; Palladino R; Russo C; Carotenuto A; Massarelli M; Vacca G; Vacchiano V; Nardone A; Triassi M; Morra VB
    Clin Chem Lab Med; 2015 Apr; 53(5):753-9. PubMed ID: 25241733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
    Guerrero AL; Tejero MA; Gutiérrez F; Martín-Polo J; Iglesias F; Laherran E; Martín-Serradilla JI; Merino S
    Neurologia; 2011 Apr; 26(3):137-42. PubMed ID: 21163235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum uric acid and multiple sclerosis.
    Sotgiu S; Pugliatti M; Sanna A; Sotgiu A; Fois ML; Arru G; Rosati G
    Neurol Sci; 2002 Oct; 23(4):183-8. PubMed ID: 12536287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory treatment of multiple sclerosis in Norway.
    Torkildsen Ø; Grytten N; Myhr KM
    Acta Neurol Scand Suppl; 2007; 187():46-50. PubMed ID: 17419828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.